Arizona State Retirement System Sells 12,258 Shares of Eli Lilly and Company (LLY)
Arizona State Retirement System reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 373,622 shares of the company’s stock after selling 12,258 shares during the quarter. Arizona State Retirement System’s holdings in Eli Lilly and were worth $30,749,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently made changes to their positions in the company. Heritage Trust Co bought a new stake in Eli Lilly and during the 1st quarter worth about $135,000. Point72 Asia Hong Kong Ltd raised its holdings in Eli Lilly and by 237.4% during the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after purchasing an additional 1,239 shares during the last quarter. Shine Investment Advisory Services Inc. bought a new stake in Eli Lilly and during the 2nd quarter worth about $148,000. Cornerstone Advisors Inc. raised its holdings in Eli Lilly and by 18.4% during the 2nd quarter. Cornerstone Advisors Inc. now owns 2,013 shares of the company’s stock worth $166,000 after purchasing an additional 313 shares during the last quarter. Finally, Penserra Capital Management LLC raised its holdings in Eli Lilly and by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after purchasing an additional 176 shares during the last quarter. 75.72% of the stock is owned by hedge funds and other institutional investors.
Shares of Eli Lilly and Company (NYSE:LLY) opened at 87.65 on Friday. The stock has a 50 day moving average price of $81.94 and a 200 day moving average price of $82.12. The firm has a market cap of $92.47 billion, a P/E ratio of 37.93 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $89.09.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. During the same quarter in the previous year, the firm earned $0.86 earnings per share. The business’s revenue was up 7.8% on a year-over-year basis. On average, equities analysts expect that Eli Lilly and Company will post $4.16 earnings per share for the current year.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 180,000 shares of the business’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the transaction, the insider now owns 123,865,804 shares of the company’s stock, valued at $10,040,562,072.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders sold 990,000 shares of company stock worth $82,949,650. Insiders own 0.20% of the company’s stock.
A number of analysts have recently commented on the company. BidaskClub raised Eli Lilly and from a “sell” rating to a “hold” rating in a research note on Wednesday, June 14th. Barclays PLC upped their price target on Eli Lilly and from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Tuesday, July 4th. BMO Capital Markets reaffirmed a “sell” rating and issued a $73.00 price target on shares of Eli Lilly and in a research note on Friday, August 4th. Berenberg Bank reaffirmed a “buy” rating and issued a $100.00 price target on shares of Eli Lilly and in a research note on Thursday, July 27th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $96.00 price target (up from $93.00) on shares of Eli Lilly and in a research note on Thursday, July 13th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have given a buy rating to the stock. Eli Lilly and has a consensus rating of “Hold” and a consensus price target of $88.42.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.